Literature DB >> 30282040

The Kinase Activity of Hematopoietic Progenitor Kinase 1 Is Essential for the Regulation of T Cell Function.

Sairy Hernandez1, Jing Qing1, Rebecca Hong Thibodeau1, Xiangnan Du1, Summer Park1, Hyang-Mi Lee1, Min Xu1, Soyoung Oh1, Armando Navarro1, Meron Roose-Girma1, Robert J Newman1, Soren Warming1, Michelle Nannini1, Deepak Sampath1, Jeong M Kim1, Jane L Grogan1, Ira Mellman2.   

Abstract

We examined hematopoietic protein kinase 1 (HPK1), whose reliance on scaffold versus kinase functions for negative immune cell regulation is poorly understood and critical to its assessment as a viable drug target. We identify kinase-dependent roles for HPK1 in CD8 T cells that restrict their anti-viral and anti-tumor responses by using HPK1 kinase-dead (HPK1.kd) knockin mice. Loss of HPK1 kinase function enhanced T cell receptor signaling and cytokine secretion in a T-cell-intrinsic manner. In response to chronic lymphocytic choriomeningitis virus (LCMV) infection or tumor challenge, viral clearance and tumor growth inhibition were enhanced in HPK1.kd mice, accompanied by an increase in effector CD8 T cell function. Co-blockade of PD-L1 further enhanced T effector cell function, resulting in superior anti-viral and anti-tumor immunity over single target blockade. These results identify the importance of HPK1 kinase activity in the negative regulation of CD8 effector functions, implicating its potential as a cancer immunotherapy target. Published by Elsevier Inc.

Entities:  

Keywords:  HPK1; cancer immunotherapy; hematopoietic progenitor kinase 1

Year:  2018        PMID: 30282040     DOI: 10.1016/j.celrep.2018.09.012

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  16 in total

Review 1.  The expanding role for small molecules in immuno-oncology.

Authors:  Rienk Offringa; Lisa Kötzner; Bayard Huck; Klaus Urbahns
Journal:  Nat Rev Drug Discov       Date:  2022-08-18       Impact factor: 112.288

2.  Hematopoietic progenitor kinase 1 down-regulates the oncogenic receptor tyrosine kinase AXL in pancreatic cancer.

Authors:  Xianzhou Song; Hironari Akasaka; Hua Wang; Reza Abbasgholizadeh; Ji-Hyun Shin; Fenglin Zang; Jiayi Chen; Craig D Logsdon; Anirban Maitra; Andrew J Bean; Huamin Wang
Journal:  J Biol Chem       Date:  2020-01-20       Impact factor: 5.157

3.  Identification of Potent Reverse Indazole Inhibitors for HPK1.

Authors:  Elsie C Yu; Joey L Methot; Xavier Fradera; Charles A Lesburg; Brian M Lacey; Phieng Siliphaivanh; Ping Liu; Dustin M Smith; Zangwei Xu; Jennifer A Piesvaux; Shuhei Kawamura; Haiyan Xu; J Richard Miller; Mark Bittinger; Alexander Pasternak
Journal:  ACS Med Chem Lett       Date:  2021-03-01       Impact factor: 4.345

4.  Discovery of Diaminopyrimidine Carboxamide HPK1 Inhibitors as Preclinical Immunotherapy Tool Compounds.

Authors:  Brandon A Vara; Samuel M Levi; Abdelghani Achab; David A Candito; Xavier Fradera; Charles A Lesburg; Shuhei Kawamura; Brian M Lacey; Jongwon Lim; Joey L Methot; Zangwei Xu; Haiyan Xu; Dustin M Smith; Jennifer A Piesvaux; J Richard Miller; Mark Bittinger; Sheila H Ranganath; David J Bennett; Erin F DiMauro; Alexander Pasternak
Journal:  ACS Med Chem Lett       Date:  2021-03-19       Impact factor: 4.345

5.  Using yeast surface display to engineer a soluble and crystallizable construct of hematopoietic progenitor kinase 1 (HPK1).

Authors:  Wai L Lau; Bradley Pearce; Heather Malakian; Iyoncy Rodrigo; Dianlin Xie; Mian Gao; Frank Marsilio; Chiehying Chang; Max Ruzanov; Jodi K Muckelbauer; John A Newitt; Daša Lipovšek; Steven Sheriff
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2020-12-22       Impact factor: 1.056

6.  Discovery of Spiro-azaindoline Inhibitors of Hematopoietic Progenitor Kinase 1 (HPK1).

Authors:  Bryan K Chan; Eileen Seward; Michael Lainchbury; Thomas F Brewer; Le An; Toby Blench; Matthew W Cartwright; Grace Ka Yan Chan; Edna F Choo; Jason Drummond; Richard L Elliott; Emanuela Gancia; Lewis Gazzard; Baihua Hu; Graham E Jones; Xifeng Luo; Andrew Madin; Sushant Malhotra; John G Moffat; Jodie Pang; Laurent Salphati; Christopher J Sneeringer; Craig E Stivala; Binqing Wei; Weiru Wang; Ping Wu; Timothy P Heffron
Journal:  ACS Med Chem Lett       Date:  2021-12-08       Impact factor: 4.345

7.  Critical role of kinase activity of hematopoietic progenitor kinase 1 in anti-tumor immune surveillance.

Authors:  Jinqi Liu; Joshua Curtin; Dan You; Stephen Hillerman; Bifang Li-Wang; Rukiye Eraslan; Jenny Xie; Jesse Swanson; Ching-Ping Ho; Simone Oppenheimer; Bethanne M Warrack; Colleen A McNaney; David M Nelson; Jordan Blum; Taeg Kim; Mark Fereshteh; Michael Reily; Petia Shipkova; Anwar Murtaza; Miguel Sanjuan; John T Hunt; Luisa Salter-Cid
Journal:  PLoS One       Date:  2019-03-26       Impact factor: 3.240

8.  Discovery of Orally Active Isofuranones as Potent, Selective Inhibitors of Hematopoetic Progenitor Kinase 1.

Authors:  Andrew P Degnan; Godwin K Kumi; Christopher W Allard; Erika V Araujo; Walter L Johnson; Kurt Zimmermann; Bradley C Pearce; Steven Sheriff; Alan Futran; Xin Li; Gregory A Locke; Dan You; John Morrison; Karen E Parrish; Caitlyn Stromko; Anwar Murtaza; Jinqi Liu; Benjamin M Johnson; Gregory D Vite; Mark D Wittman
Journal:  ACS Med Chem Lett       Date:  2021-02-19       Impact factor: 4.345

Review 9.  Advancing targeted protein degradation for cancer therapy.

Authors:  Brandon Dale; Meng Cheng; Kwang-Su Park; H Ümit Kaniskan; Yue Xiong; Jian Jin
Journal:  Nat Rev Cancer       Date:  2021-06-15       Impact factor: 60.716

Review 10.  A perspective on HPK1 as a novel immuno-oncology drug target.

Authors:  Sansana Sawasdikosol; Steven Burakoff
Journal:  Elife       Date:  2020-09-08       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.